Geest, Vincent http://orcid.org/0000-0001-5777-331X
Oblak, Janja Pretnar
Popović, Katarina Šurlan
Nawabi, Jawed
Elsayed, Sarah
Friedrich, Constanze
Böhmer, Maik
Akkurt, Burak
Sporns, Peter
Morotti, Andrea
Schlunk, Frieder
Steffen, Paul
Broocks, Gabriel
Meyer, Lukas
Hanning, Uta
Thomalla, Götz
Gellissen, Susanne
Fiehler, Jens
Frol, Senta
Kniep, Helge
Funding for this research was provided by:
Universitätsklinikum Hamburg-Eppendorf (UKE)
Article History
Received: 2 April 2024
Revised: 29 April 2024
Accepted: 30 April 2024
First Online: 22 May 2024
Declarations
:
: Götz Thomalla reports funding from the European Commission; personal consulting fees from Acandis, AstraZeneca, Bayer, Boehringer Ingelheim, and Stryker; personal payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Acandis, Alexion, Marin, Bayer, Boehringer Ingelheim, BristolMyersSquibb/Pfizer, Daiichi Sankyo, and Stryker; participation as DSMB member for the TEA Stroke Trial (no payments) and ReSCInD trial (no payments); work as a speaker of the Commission for Cerebrovascular Diseases of the German Society of Neurology (DGN; no payments); and membership of the Board of Directors of the European Stroke Organisation (ESO; no payments). Jens Fiehler reports funding from the European Commission; personal consulting fees from Acandis, Cerenovus, Medtronic, Microvention, Phenox, Stryker, and Roche; consulting at Philips (no payments); payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Penumbra and Tonbridge; support for attending meetings or travel from Medtronic and Penumbra; stock or stock options from Tegus Medical, Eppdata, and Vastrax; and participation in a Data Safety Monitoring Board or Advisory Board at Phenox (personal fees) and Stryker (personal fees) and is a past president of ESMINT.